MedTrace Logo

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

NCT06095986 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-06-12

No results posted yet for this study

Summary

The objectives of this study is to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients with Primary Sclerosing Cholangitis

Conditions

  • Primary Sclerosing Cholangitis

Interventions

DRUG

Aramchol meglumine

Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)

Sponsors & Collaborators

  • Virginia Commonwealth University

    collaborator OTHER

  • Galmed Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Arun Sanyal, MD · The Sanyal Institute for Liver Disease & Metabolic Health at VCU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2026-09-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06095986 on ClinicalTrials.gov